Evaluation of appropriate use of bisphosphonates and denosumab in patients with cancer.
| Autor: | Gyori, Derek J, Bullington, Susan M, Crawford, Brooke S, Vernon, Veronica P |
|---|---|
| Předmět: |
DENOSUMAB
THERAPEUTIC use of monoclonal antibodies THERAPEUTIC use of vitamin D ANTIANDROGENS BONE metastasis BONE diseases CALCIUM CANCER patients DIPHOSPHONATES DRUG prescribing MEDICAL records PATIENT education PHYSICIAN practice patterns RETROSPECTIVE studies AROMATASE inhibitors MEDICATION therapy management PHOTON absorptiometry ACQUISITION of data methodology DISEASE risk factors |
| Zdroj: | Journal of Oncology Pharmacy Practice; Mar2020, Vol. 26 Issue 2, p286-292, 7p, 1 Diagram, 4 Charts |
| Abstrakt: | Background: National guidelines recommend screening and treatment for cancer-related bone disease and continued monitoring of bone-modifying agents. It is unclear whether a standardized screening tool is utilized to identify eligible patients and ensure appropriate supportive care is implemented. The purpose of this study was to evaluate current prescribing practices and optimize management of bone-modifying agents. Methods: A retrospective chart review was performed to identify patients who received hormone deprivation therapy or had bone metastases through Hematology/Oncology or Urology clinics from 1 November 2016 to 31 October 2017. The primary endpoints of this study were the incidence of completed baseline dual-energy X-ray absorptiometry (DEXA) scan for patients on hormone deprivation therapy and percent of patients started on a bone-modifying agent for the prevention of skeletal-related events secondary to bone metastasis. Secondary endpoints included percent of patients with dental examinations prior to initiation, adequate calcium and vitamin D supplementation, incidence of osteonecrosis of the jaw or flu-like symptoms and education, and percent of bisphosphonate doses appropriately adjusted based on renal function. Results: A total of 375 patients were assessed for baseline DEXA scans and bone-modifying therapy. Of the 226 patients on hormone deprivation therapy, 111 (49%) patients were appropriately screened with a DEXA scan prior to initiation of hormone deprivation therapy. Among the 149 patients with bone metastases, only 94 (63.1%) patients were started on a bone-modifying agent. Conclusions: Opportunities have been identified to optimize management of patients with cancer-related bone disease. Implementation of standardized tools may increase the rate of appropriate screening and initiation of bone-modifying therapy when warranted. [ABSTRACT FROM AUTHOR] |
| Databáze: | Complementary Index |
| Externí odkaz: |
|